TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

Tim Orth Memorial Foundation basketball jamboree is Saturday in Glencoe, and as usual all proceeds from that night will go to help kids and their families with medical bills. This ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

The availability of a follicular lymphoma data library has the potential to improve researchers' understanding of the disease's biology. Providing researchers with access to robust multimodal data ...